Thymosin Alpha-1 vs Thymosin Beta-4

Tα1 modulates both innate and adaptive immune responses by stimulating the differentiation and maturation of T-cells, dendritic cells, and natural killer cells. It upregulates MHC class I and II expression, enhancing antigen presentation. It also promotes the production of key cytokines including interferon-γ and interleukin-2, which are central to immune surveillance.

Thymosin alpha-1 (thymalfasin; Zadaxin) is a 28-amino-acid synthetic peptide corresponding to the N-terminal sequence of prothymosin alpha, developed as a biological response modifier with established clinical use outside the United States for chronic viral hepatitis and as an immune adjuvant in cancer and immunocompromised patients. Thymalfasin modulates innate and adaptive immune responses by upregulating Toll-like receptor expression and dendritic cell maturation, enhancing T-helper 1 cytokine signaling, and potentiating antigen-specific T-cell responses in settings of impaired immune function. A prospective multicenter randomized controlled trial demonstrated that combination therapy with thymosin alpha-1 and entecavir improved serological outcomes in HBV-related compensated cirrhosis compared to entecavir alone, and cumulative RCT evidence supports its role as an immune adjuvant in hepatitis B and C treatment. Thymosin alpha-1 is approved in approximately 35 countries — including China, Italy, and other Asian and Eastern European markets — for hepatitis B and hepatitis C adjuvant therapy, but has not received FDA approval in the United States and is available in US-adjacent research contexts only as an investigational compound. Thymosin alpha-1 dosage: in approved clinical protocols (hepatitis B adjuvant therapy), thymalfasin is administered as 1.6 mg subcutaneously twice weekly for 26–52 weeks. This dosing schedule is derived from the pivotal trials conducted by SciClone Pharmaceuticals, which developed Zadaxin. In COVID-19 research during 2020–2021, Chinese clinical centers studied thymosin alpha-1 as an immune adjuvant in severe and critical COVID-19 patients, with published observational and small RCT data; this research context brought renewed attention to the peptide's immune-modulating properties outside the hepatitis indication. Within the recovery and immune-support peptide landscape, thymosin alpha-1 is most closely compared to thymosin beta-4 (TB-500) — the two peptides share the thymosin nomenclature but have distinct mechanisms and research profiles. Thymosin alpha-1 is an immune activator (TH1 upregulation); thymosin beta-4 is primarily studied for tissue repair and actin dynamics. Providers offering immune-modulating peptide compounds are listed in the PeptideBase directory.

Sequesters G-actin monomers via its WH2 domain, regulating actin dynamics and cell migration. Upregulates metalloproteinases and growth factors for tissue remodeling. Promotes cardiomyocyte survival and angiogenesis post-injury.

Thymosin beta-4 (Tb4) is an endogenous 43-amino-acid protein ubiquitously expressed in mammalian tissues, best characterized for its role in G-actin sequestration, cell migration promotion, and tissue repair signaling across multiple organ systems. Tb4 exerts reparative effects by upregulating angiogenesis, modulating inflammation, and generating the anti-fibrotic tetrapeptide Ac-SDKP through enzymatic cleavage; preclinical models in cardiac, renal, and musculoskeletal tissue have demonstrated measurable regenerative outcomes following exogenous administration. Published literature supports anti-fibrotic activity in animal models of renal fibrosis and cardiovascular injury, and the Tb4-Ac-SDKP pathway has been characterized as a plausible target in fibrosis biology; however, clinical translation has been limited, with a Phase 2 cardiac repair trial that did not demonstrate efficacy sufficient to advance to Phase 3. Exogenous thymosin beta-4 has no FDA approval for any indication; it is available only as a research compound, and the substantial gap between preclinical findings and human clinical outcomes represents an important limitation of the current evidence base. Thymosin beta-4 vs TB-500 TB-500 is a commercial label used for synthetic thymosin beta-4 in the peptide research market. The underlying compound is the same 43-amino-acid sequence as endogenous Tb4; "TB-500" originated as a brand name from veterinary product contexts and has since become the predominant research market name for synthetic thymosin beta-4. When research suppliers, athletes, or forum communities reference TB-500, they are referring to synthetic Tb4 — the same compound profiled here. The TB-500 label is commonly associated with injectable research peptide use; the thymosin beta-4 label is associated with the biochemical and medical literature. Some suppliers sell "TB-4 Frag" (the Ac-SDKP tetrapeptide fragment), which is a distinct, smaller molecule derived from enzymatic cleavage of Tb4, not the full-length thymosin beta-4 protein. Thymosin beta-4 dosage in research contexts: Research protocols described in preclinical literature and anecdotal human use reports typically reference doses in the range of 2–5 mg per injection, administered subcutaneously or intramuscularly, with a loading phase of 2–4 injections per week followed by a maintenance phase of 1–2 injections per week. These dosage figures are derived from research compound use and veterinary contexts, not from FDA-approved human clinical protocols — no approved human dosing exists. The Phase 2 cardiac repair trial that administered intravenous Tb4 used significantly different dose and route parameters. Thymosin beta-4 is available only as a research compound; it is not FDA-approved for any human indication and is not available through licensed prescription channels.